This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Horizon Pharma plc

Drug Names(s): injectable testosterone, Testosterone Enanthate Injection

Description: Delatestryl is a testosterone replacement therapy designed for intramuscular administration. It consists of testosterone enanthate, a derivative of testosterone.

Deal Structure: Indevus and Savient
In January 2006, Indevus announced the closing of the acquisition of the U.S. rights to Delatestryl from Savient. Under the terms of the agreement Indevus will pay Savient $5.0 million upon closing of the transaction and will purchase the Delatestryl inventory over the next 24 months.

Indevus will pay royalties to Savient for 3 years following the closing of the transaction based upon the net sales of Delatestryl. The royalty rate will be 5% on the first $5 million of cumulative net sales, increasing to 10% on cumulative net sales between $5 million and $10 million, and will rise to 25% on cumulative net sales above $10 million.

Endo and Indevus
In January 2009, Endo Pharmaceuticals and Indevus Pharmaceuticals announced that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash,...See full deal structure in Biomedtracker

Partners: Bristol-Myers Squibb Company Endo International plc

Delatestryl News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug